

Please add the following claims:

✓ --89. A method of inhibiting B lymphocyte proliferation in a mammal, comprising administering to the mammal a composition that comprises a soluble form of a ztnf4 receptor, wherein the soluble ztnf4 receptor binds ztnf4.

90. The method of claim 89, wherein the soluble ztnf4 receptor is a soluble form of the transmembrane activator and calcium-modulator and cyclophilin ligand-interactor (TACI) polypeptide, wherein the TACI polypeptide has an amino acid sequence consisting of SEQ ID NO:6.

91. The method of claim 90, wherein the soluble form of TACI consists of an extracellular domain of TACI.

92. The method of claim 90, wherein the soluble form of TACI comprises amino acid residues 25 to 104 of SEQ ID NO:6.

02 93. The method of claim 92, wherein the soluble form of TACI consists of amino acid residues 25 to 104 of SEQ ID NO:6.

94. The method of claim 92, wherein the soluble form of TACI comprises amino acid residues 1 to 154 of SEQ ID NO:6.

95. The method of claim 94, wherein the soluble form of TACI consists of amino acid residues 1 to 154 of SEQ ID NO:6.

96. The method of claim 92, wherein the soluble form of TACI comprises amino acid residues 1 to 166 of SEQ ID NO:6.

97. The method of claim 96, wherein the soluble form of TACI consists of amino acid residues 1 to 166 of SEQ ID NO:6.

98. The method of claim 89, wherein the soluble ztnf4 receptor is a soluble form of the BCMA polypeptide, wherein the BCMA polypeptide has an amino acid sequence consisting of SEQ ID NO:8.

99. The method of claim 98, wherein the soluble form of BCMA polypeptide consists of an extracellular domain of BCMA.

100. The method of claim 98, wherein the soluble form of BCMA comprises amino acid residues 1 to 48 of SEQ ID NO:8.

101. The method of claim 100, wherein the soluble form of BCMA consists of amino acid residues 1 to 48 of SEQ ID NO:8.

102. The method of claim 89, wherein the soluble form of the ztnf4 receptor comprises a fusion protein that consists of a first portion and a second portion, wherein the first portion and second portion are joined by a peptide bond, wherein the first portion of the fusion protein comprises an extracellular domain of a ztnf4 receptor, and wherein the second portion of the fusion protein is an immunoglobulin heavy chain constant region.

103. The method of claim 102, wherein the immunoglobulin heavy chain constant region is a human immunoglobulin heavy chain constant region.

104. The method of claim 103, wherein the human immunoglobulin heavy chain constant region is a human immunoglobulin heavy chain constant region of IgG1.

105. The method of claim 102, wherein the soluble form of the ztnf4 receptor comprises a multimer of fusion proteins.

106. The method of claim 105, wherein the soluble form of the ztnf4 receptor comprises a dimer of fusion proteins.

107. The method of claim 102, wherein the ztnf4 receptor is the transmembrane activator and calcium-modulator and cyclophilin ligand-interactor (TACI) polypeptide, wherein the TACI polypeptide has an amino acid sequence consisting of SEQ ID NO:6.

108. The method of claim 107, wherein the immunoglobulin heavy chain constant region is a human immunoglobulin heavy chain constant region.

109. The method of claim 108, wherein the human immunoglobulin heavy chain constant region is a human immunoglobulin heavy chain constant region of IgG1.

576
B2
110. The method of claim 107, wherein the soluble form of the ztnf4 receptor comprises a multimer of fusion proteins.

111. The method of claim 110, wherein the soluble form of the ztnf4 receptor comprises a dimer of fusion proteins.

112. The method of claim 102, wherein the ztnf4 receptor is the BCMA polypeptide, wherein the BCMA polypeptide has an amino acid sequence consisting of SEQ ID NO:8.

113. The method of claim 112, wherein the immunoglobulin heavy chain constant region is a human immunoglobulin heavy chain constant region.

Acac.
114. The method of claim 113, wherein the human immunoglobulin heavy chain constant region is a human immunoglobulin heavy chain constant region of IgG1.

115. The method of claim 112, wherein the soluble form of the ztnf4 receptor comprises a multimer of fusion proteins.

116. The method of claim 115, wherein the soluble form of the ztnf4 receptor comprises a dimer of fusion proteins.--
